[1]张 杰.达菲林与地诺孕素在卵巢型子宫内膜异位症患者腹腔镜手术后的应用效果比较[J].医学信息,2025,38(07):125-128.[doi:10.3969/j.issn.1006-1959.2025.07.024]
　ZHANG Jie.Comparison of the Application Effect of Dophereline and Dienogest in Patients with Ovarian Endometriosis After Laparoscopic Surgery[J].Journal of Medical Information,2025,38(07):125-128.[doi:10.3969/j.issn.1006-1959.2025.07.024]
点击复制

达菲林与地诺孕素在卵巢型子宫内膜异位症患者腹腔镜手术后的应用效果比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年07期
页码:
125-128
栏目:
论著
出版日期:
2025-04-01

文章信息/Info

Title:
Comparison of the Application Effect of Dophereline and Dienogest in Patients with Ovarian Endometriosis After Laparoscopic Surgery
文章编号:
1006-1959（2025）07-0125-04
作者:
张 杰
天津港口医院妇产科，天津 300450
Author(s):
ZHANG Jie
Department of Obstetrics and Gynecology, Port Hospital of Tianjin, Tianjin 300450, China
关键词:
卵巢型子宫内膜异位症; 达菲林; 地诺孕素; 腹腔镜手术; 卵巢储备功能
Keywords:
Ovarian endometriosis;  Diphereline;  Dinogest;  Laparoscopic surgery;  Ovarian reserve function
分类号:
R711.71
DOI:
10.3969/j.issn.1006-1959.2025.07.024
文献标志码:
A
摘要:
目的 研究达菲林与地诺孕素在卵巢型子宫内膜异位症（OEM）患者腹腔镜手术后的应用效果。方法 经随机数字表法将天津港口医院2021年1月-2022年9月收治的OEM患者60例分为地诺孕素组30例与达菲林组30例。达菲林组采用达菲林注射治疗，地诺孕素组给予地诺孕素口服治疗，比较两组疼痛症状[慢性疼痛分级问卷法（CPG）]、卵巢储备功能[抗苗勒管激素（AMH）、卵泡刺激素（FSH）、窦状卵泡数（AFC）]、血清糖类抗原125（CA125）水平、药物副作用（围绝经期症状、阴道淋漓出血、突发性出血、骨密度下降）、复发情况。结果 与治疗前比较，两组治疗后非经期下腹痛、痛经、性交痛CPG评分降低，且地诺孕素组治疗后非经期下腹痛、痛经、性交痛CPG评分低于达菲林组（P＜0.05）；与治疗前比较，两组治疗后AMH、FSH、AFC指标降低，但地诺孕素组治疗后AMH、FSH、AFC指标高于达菲林组（P＜0.05）；与治疗前比较，两组治疗后血清CA125水平降低，且地诺孕素组治疗后血清CA125水平低于达菲林组（P＜0.05）；地诺孕素组药物副作用发生率及治疗12个月后复发率低于达菲林组（P＜0.05）。结论 达菲林与地诺孕素在OEM腹腔镜手术后均具有确切效果，可缓解患者疼痛症状，改善其卵巢储备功能，下调血清CA-125水平，但后者效果更佳，复发风险更小，用药安全性相对更高。
Abstract:
Objective To study the application effect of dipherelin and dinogest in patients with ovarian endometriosis (OEM) after laparoscopic surgery. Methods According to the random number table method, 60 OEM patients admitted to the Port Hospital of Tianjin from January 2021 to September 2022 were divided into 30 patients in the dinogest group and 30 patients in the dipherelin group. The dipherelin group was treated with dipherelin injection, and the dinogest group was treated with oral dinogest. The pain symptoms [chronic pain grading questionnaire (CPG)], ovarian reserve function [anti-Müllerian hormone (AMH), follicle stimulating hormone (FSH), antral follicle count (AFC)], serum carbohydrate antigen 125 (CA125) level, drug side effects (perimenopausal symptoms, vaginal bleeding, sudden bleeding, bone mineral density decreased), recurrence were compared between the two groups. Results Compared with before treatment, the CPG scores of non-menstrual lower abdominal pain, dysmenorrhea and dyspareunia in the two groups after treatment were decreased, and the CPG scores of non-menstrual lower abdominal pain, dysmenorrhea and dyspareunia in the dinogest group after treatment were lower than those in the dipherelin group (P<0.05). Compared with before treatment, the indexes of AMH, FSH and AFC in the two groups decreased after treatment, but the indexes of AMH, FSH and AFC in the dienogest group were higher than those in the dipherelin group after treatment(P<0.05). Compared with before treatment, the level of serum CA125 in the two groups decreased after treatment, and the level of serum CA125 in the dinogest group was lower than that in the diphereline group after treatment(P<0.05). The incidence of drug side effects and the recurrence rate after 12 months of treatment in the dienogest group were lower than those in the dipherelin group(P<0.05). Conclusion Diphereline and dinogest both have exact effects after OEM laparoscopic surgery, which can relieve pain symptoms, improve ovarian reserve function, and down-regulate serum CA-125 level. However, the latter has better effect, less risk of recurrence, and relatively higher drug safety.

参考文献/References:

[1]吴雯婷,沈企隆,董婕,等.地诺孕素对改善子宫内膜异位症患者性激素水平病灶大小及临床疗效的影响[J].中国妇幼保健,2023,38(17):3199-3202.[2]黄琦,崔彬彬,周丽华,等.地诺孕素对子宫内膜异位症腹腔镜手术后疗效的影响[J].局解手术学杂志,2023,32(7):633-636.[3]徐小敏,江秀秀,林俊.腹腔镜保守手术联合GnRH-a对子宫内膜异位症患者卵巢功能及妊娠率影响研究[J].中国实用妇科与产科杂志,2021,37(7):786-789.[4]赵庆,唐萍,李爽.腹腔镜术后辅助地屈孕酮治疗子宫内膜异位症对血清E-cadherin、CA125、HE4的影响[J].分子诊断与治疗杂志,2023,15(5):759-763.[5]赵梦丹,李君琴,杨佩磊,等.不同促性腺激素释放激素激动剂治疗子宫内膜异位症的应用情况和疗效分析[J].中国现代应用药学,2020,37(5):604-607.[6]杜昕,秦海霞.GnRH-a序贯地诺孕素治疗子宫内膜异位症术后痛经的有效性分析[J].临床药物治疗杂志,2023,21(5):39-44.[7]姚莉,吕艳春,蔡婉明,等.桂枝茯苓丸联合地诺孕素治疗子宫内膜异位症的临床研究[J].现代药物与临床,2022,37(11):2588-2592.[8]徐学麟,周欢珍,高雅洁,等.术前使用曲普瑞林对围绝经期子宫内膜异位症患者异位细胞的增殖、侵袭影响[J].中国临床药理学杂志,2022,38(18):2120-2123.[9]中国医师协会妇产科医师分会,中华医学会妇产科学分会子宫内膜异位症协作组,冷金花.子宫内膜异位症诊治指南(第三版)[J].中华妇产科杂志,2021,56(12):812-824.[10]刘香菊,韩洁,勾明月,等.超声引导下穿刺联合亮丙瑞林治疗中重度卵巢型子宫内膜异位症患者术后妊娠结局的影响因素分析[J].河北医科大学学报,2022,43(6):662-665,710.[11]胡江辉,吴春丽,吴丽华.注射用醋酸曲普瑞林联合丹那唑对子宫内膜异位症患者基质金属蛋白酶水平的影响[J].广东医学,2020,41(12):1268-1271.[12]肖莉莎,姚青青,段世军,等.子宫内膜异位症的激素治疗对卵巢纤维化和卵巢储备的影响[J].现代生物医学进展,2022,22(9):1681-1686.[13]王久兰,何伟,周夏伶,等.地诺孕素、亮丙瑞林辅助治疗卵巢子宫内膜异位囊肿的临床效果比较[J].中国妇产科临床杂志,2022,23(3):275-277.[14]刘小慧,陈晓林,周明辉,等.GnRHa低剂量长方案治疗对卵巢型子宫内膜异位症患者术后妊娠的影响[J].中国妇产科临床杂志,2022,23(3):303-304.[15]梁海莹,周雪勤,胡明淼,等.地诺孕素与促性腺激素释放激素激动剂类药物治疗对子宫内膜异位症手术患者血清糖类抗原125、骨密度、雌二醇和肿块大小的影响[J].中国性科学,2023,32(3):54-58.[16]张森,常茹,郭超.腹腔镜手术联合抗感染及地诺孕素治疗子宫内膜异位症的临床研究[J].局解手术学杂志,2023,32(8):708-711.[17]邵铃,王鸿燕,杨志英.地诺孕素联合腹腔镜手术治疗子宫内膜异位症不孕对患者血清AMH、VEGF和临床妊娠影响[J].中国计划生育学杂志,2023,31(11):2593-2596,2600.[18]彭海英,胡卫忠,刘建,等.孕三烯和曲普瑞林治疗子宫内膜异位症的疗效比较[J].西部医学,2021,33(5):727-730.[19]曹啸俊,刘姝灵,陆舜华,等.地诺孕素对卵巢子宫内膜异位囊肿患者术后复发及卵巢储备功能的影响[J].实用药物与临床,2021,24(9):809-812.[20]凌霞,陈君霞.地诺孕素应用于卵巢子宫内膜异位囊肿保守治疗的临床效果研究[J].中国妇幼保健,2023,38(24):4879-4883.[21]姜淑丽,张欢欢,郝学平.腹腔镜下卵巢子宫内膜异位症囊肿剔除术对患者卵巢皮质剥除、卵巢功能及预后影响[J].中国计划生育学杂志,2021,29(12):2546-2550.

更新日期/Last Update: 1900-01-01